Please assess the completion status of the following clinical trial:

Trial Title: Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed acute myeloid leukemia (AML) meeting 1 of the following criteria:~  * At least 60 years of age and not a candidate for or refused standard induction treatment~ * Poor risk cytogenetics~ * AML following antecedent hematologic disorder~ * Therapy-related AML~ * Secondary AML~* No granulocytic sarcoma as sole site of disease~* No active CNS disease or CNS relapse~* ECOG performance status 0-2~* Life expectancy \> 6 months~* Total bilirubin \< 2.0 mg/dL~* Creatinine \< 2.0 mg/dL~* AST and ALT \< 2.5 times upper limit of normal~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No NYHA class III or IV congestive heart failure~* No uncontrolled infection~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine that are not easily managed~* No other uncontrolled illness including, but not limited to, any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Serious cardiac arrhythmia~ * Psychiatric illness or social situations that would preclude compliance with study requirements~* No active second malignancy involving the blood or marrow or likely to progress and require therapy in the next 6 months~* No prior therapy for AML except emergency leukapheresis or hydroxyurea for leukocytosis~* No prior azacitidine or decitabine~* No prior cytarabine or other conventional chemotherapy agents for antecedent hematologic disorders~  * Prior myeloid growth factors, recombinant erythropoietin, thalidomide, or lenalidomide allowed~* No concurrent palliative radiotherapy~* No other concurrent investigational agents~* No other concurrent direct anti-leukemia therapy~* No concurrent combination antiretroviral therapy for HIV-positive patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (chemotherapy) (Type: EXPERIMENTAL): Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).